vedolizumab   Click here for help

GtoPdb Ligand ID: 7437

Synonyms: Entyvio® | LDP-02 | LDP02 | MLN-0002 | MLN-002 | MLN002
Approved drug Immunopharmacology Ligand
vedolizumab is an approved drug (FDA and EMA (2014))
Compound class: Antibody
Comment: Vedolizumab is a gut-selective monoclonal antibody that acts as an integrin antagonist by binding to α4β7 integrins on the surface of gastrointestinal-homing T lymphocytes.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
PB016 n/aPolpharma Biologics/Fresenius KabiPhase 3moderate-severe active ulcerative colitis and Crohn's disease
Click here for help
Bioactivity Comments
In vitro, vedolizumab inhibits specific binding of α4β7 +ve lymphoma cells to immobilised MADCAM1 or fibronectin with IC50 values of 0.39nM and 0.14nM respectively [2]. Soler et al. (2009) also show by FACS analysis that vedolizumab binds specifically to cells exogenously expressing the α4 and β7 intergrin proteins [2].
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin α4β7 Primary target of this compound Hs Antibody Antagonist 8.3 pIC50 - 1
⤷ pIC50 8.3 (IC50 5.34x10-9 M) [1]
Description: Binding to HuT-78 cells
Ligand mentioned in the following text fields